Regeneron Pharmaceuticals Inc 2018 Q2 Institutional Investor Sentiment Better Than Expected

October 11, 2018 - By Catherine Diaz

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Sentiment for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) institutional sentiment increased to 1.19 in Q2 2018. Its up 0.14, from 1.05 in 2018Q1. The ratio has improved, as 238 funds started new and increased equity positions, while 200 cut down and sold positions in Regeneron Pharmaceuticals Inc. The funds in our partner’s database now hold: 70.25 million shares, up from 69.33 million shares in 2018Q1. Also, the number of funds holding Regeneron Pharmaceuticals Inc in their top 10 equity positions was flat from 8 to 8 for the same number . Sold All: 43 Reduced: 157 Increased: 171 New Position: 67.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $40.98 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 27.57 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

The stock decreased 0.60% or $2.28 during the last trading session, reaching $379.66. About 238,094 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 12.51% since October 11, 2017 and is downtrending. It has underperformed by 28.13% the S&P500.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on November, 14. They expect $5.03 EPS, up 51.51 % or $1.71 from last year’s $3.32 per share. REGN’s profit will be $542.96M for 18.87 P/E if the $5.03 EPS becomes a reality. After $4.70 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.02 % EPS growth.

Hellman Jordan Management Co Inc Ma holds 13.83% of its portfolio in Regeneron Pharmaceuticals, Inc. for 50,000 shares. Lagoda Investment Management L.P. owns 59,978 shares or 8.6% of their US portfolio. Moreover, Healthcor Management L.P. has 6.85% invested in the company for 625,000 shares. The New York-based Senzar Asset Management Llc has invested 5.2% in the stock. Sustainable Growth Advisers Lp, a Connecticut-based fund reported 1.01 million shares.

Since January 1, 0001, it had 0 insider purchases, and 8 sales for $143.17 million activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

Ratings analysis reveals 30% of Regeneron’s analysts are positive. Out of 10 Wall Street analysts rating Regeneron, 3 give it “Buy”, 1 “Sell” rating, while 6 recommend “Hold”. The lowest target is $29000 while the high is $42000. The stock’s average target of $387.86 is 2.16% above today’s ($379.66) share price. REGN was included in 14 notes of analysts from April 17, 2018. The stock has “Underweight” rating by Barclays Capital on Monday, August 6. The firm has “Buy” rating by Oppenheimer given on Wednesday, June 27. The firm has “Equal-Weight” rating given on Friday, May 4 by Morgan Stanley. As per Friday, August 3, the company rating was maintained by Morgan Stanley. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Sell” rating given on Wednesday, May 23 by Barclays Capital. The stock has “Hold” rating by Canaccord Genuity on Friday, August 3. The company was maintained on Friday, May 4 by BMO Capital Markets. The firm earned “Buy” rating on Tuesday, April 17 by Credit Suisse. Argus Research maintained the stock with “Buy” rating in Monday, July 16 report. The company was maintained on Friday, July 13 by Morgan Stanley.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Seekingalpha.com which released: “Amarin up 14% amid conference presentation” on October 03, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on October 01, 2018, Nasdaq.com published: “Bluebird Bio Stock May Have Upside of at Least 60 Percent” on September 13, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Seekingalpha.com and their article: “FDA to review sBLA for Praluent Injection as potential treatment to reduce MACE” published on September 12, 2018 as well as Fool.com‘s news article titled: “3 Top Biotech Stocks to Buy in October” with publication date: October 08, 2018.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: